LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYSLE study

Abstractsinfection, urinary tract infection and infusion-related reactions (1.3% each) among obinutuzumab-treated patients.Conclusions Obinutuzumab was superior to placebo in achieving the primary and five key secondary endpoints.No new safety signals were identified.ALLEGORY provides evidence that obinutuzumab, when added to ST, is more effective for active SLE than ST alone.